Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation

Messenger RNA-based vaccines have the potential to trigger robust cytotoxic immune responses, which are essential for fighting cancer and infectious diseases like HIV. Dendritic Cells (DCs) are choice targets for mRNA-based vaccine strategies, as they link innate and adaptive immune responses and ar...

Full description

Saved in:
Bibliographic Details
Published in:Biomaterials 2019-03, Vol.195, p.23-37
Main Authors: Coolen, Anne-Line, Lacroix, Céline, Mercier-Gouy, Perrine, Delaune, Emilie, Monge, Claire, Exposito, Jean-Yves, Verrier, Bernard
Format: Article
Language:English
Subjects:
Animals
Bioengineering
Biomaterials
Cell-penetrating peptide (CPPs)
Cell-Penetrating Peptides - chemistry
Chemical Sciences
Dendritic cells
Dendritic Cells - metabolism
Endocytosis - physiology
Galenic pharmacology
Human health and pathology
Humans
Hépatology and Gastroenterology
Immunology
Immunotherapy
Infectious diseases
LAH4-L1
Life Sciences
Microbiology and Parasitology
mRNA-vaccine
Nanoparticle (NP)
Nanoparticles - chemistry
Phagocytosis - physiology
Pharmaceutical sciences
poly(lactic acid) (PLA)
Polyesters - chemistry
Polymers
RNA, Messenger - chemistry
RNA, Messenger - metabolism
Vaccinology
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Messenger RNA-based vaccines have the potential to trigger robust cytotoxic immune responses, which are essential for fighting cancer and infectious diseases like HIV. Dendritic Cells (DCs) are choice targets for mRNA-based vaccine strategies, as they link innate and adaptive immune responses and are major regulators of cytotoxic and humoral adaptive responses. However, efficient delivery of antigen-coding mRNAs into DC cytosol has been highly challenging. In this study, we developed an alternative to lipid-based mRNA delivery systems, using poly(lactic acid) nanoparticles (PLA-NPs) and cationic cell-penetrating peptides as mRNA condensing agent. The formulations are assembled in two steps: (1) formation of a polyplex between mRNAs and amphipathic cationic peptides (RALA, LAH4 or LAH4-L1), and (2) adsorption of polyplexes onto PLA-NPs. LAH4-L1/mRNA polyplexes and PLA-NP/LAH4-L1/mRNA nanocomplexes are taken up by DCs via phagocytosis and clathrin-dependent endocytosis, and induce strong protein expression in DCs in vitro. They modulate DC innate immune response by activating both endosome and cytosolic Pattern Recognition Receptors (PRRs), and induce markers of adaptive responses in primary human DCs in vitro, with prevalent Th1 signature. Thus, LAH4-L1/mRNA and PLA-NP/LAH4-L1/mRNA represent a promising platform for ex vivo treatment and mRNA vaccine development.
ISSN:0142-9612
1878-5905
DOI:10.1016/j.biomaterials.2018.12.019